文献速递胸部CT

美国预防服务工作组资格标准变更前ACR肺CT筛查报告与数据系统的系统评价与Meta分析:2014年至2021年

ACR Lung CT Screening Reporting and Data System, a Systematic Review and Meta-Analysis Before Change in US Preventative Services Taskforce Eligibility Criteria: 2014 to 2021.
PubMed 文献 · J Am Coll Radiol · 2023-06-08

该系统评价与Meta分析纳入24项美国低剂量CT肺癌筛查研究,共36,211次检查、32,817例患者,评估2014至2021年Lung-RADS评分分布与阳性预测值。结果显示Lung-RADS 1-2评分低于ACR预期(84.4% vs 90%),3和4类高于预期(8.7% vs 5%,6.5% vs 4%),Lung-RADS 3-4的PPV为13.1%,低于ACR最低估计21%。作者认为Lung-RADS分类可能需要重新审视以更好符合真实筛查人群。

要点

  • Lung-RADS 1-2类实际比例为84.4%,低于ACR预期的90%。
  • Lung-RADS 3和4类实际比例为8.7%和6.5%,均高于ACR预期的5%和4%。
  • Lung-RADS 3-4类合并PPV为13.1%,低于ACR最低估计21%;Lung-RADS 4类PPV为28.6%。

核心结论

  • 文献中Lung-RADS评分和PPV与ACR自身估计不一致,提示Lung-RADS分类可能需要重新审视以更好符合真实筛查人群;本研究为筛查指南拓宽前提供基准,并为未来肺癌筛查和Lung-RADS数据报告提供指导。

研究设计与样本

  • 注册的系统评价与Meta分析,检索MEDLINE、Embase、CINAHL和Web of Science,遵循PRISMA指南;纳入24项美国机构低剂量CT肺癌筛查研究,报告2014至2021年Lung-RADS评分。

诊断标准与关键数值

  • Meta分析Lung-RADS 1-2类合并比例为84.4%(95%CI 83.3-85.6),ACR预期为90%(P < .001);Lung-RADS 3类为8.7%(95%CI 7.6-10.1),ACR预期为5%(P < .001);Lung-RADS 4类为6.5%(95%CI 5.70-7.4),ACR预期为4%(P < .001)。

临床应用与阅片要点

  • 作者认为Lung-RADS分类可能需要重新审视以更好符合真实筛查人群;本研究可为未来肺癌筛查和Lung-RADS数据报告提供指导。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To review Lung CT Screening Reporting and Data System (Lung-RADS) scores from 2014 to 2021, before changes in eligibility criteria proposed by the US Preventative Services Taskforce.

METHODS: A registered systematic review and meta-analysis was conducted in MEDLINE, Embase, CINAHL, and Web of Science in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines; eligible studies examined low-dose CT (LDCT) lung cancer screening at institutions in the United States and reported Lung-RADS from 2014 to 2021. Patient and study characteristics, including age, gender, smoking status, pack-years, screening timeline, number of individual patients, number of unique studies, Lung-RADS scores, and positive predictive value (PPV) were extracted. Meta-analysis estimates were derived from generalized linear mixed modeling.

RESULTS: The meta-analysis included 24 studies yielding 36,211 LDCT examinations for 32,817 patient encounters. The meta-analysis Lung-RADS 1-2 scores were lower than anticipated by ACR guidelines, at 84.4 (95% confidence interval [CI] 83.3-85.6) versus 90% respectively (P < .001). Lung-RADS 3 and 4 scores were both higher than anticipated by the ACR, at 8.7% (95% CI 7.6-10.1) and 6.5% (95% CI 5.707.4), compared with 5% and 4%, respectively (P < .001). The ACR's minimum estimate of PPV for Lung-RADS 3 to 4 is 21% or higher; we observed a rate of 13.1% (95% CI 10.1-16.8). However, our estimated PPV rate for Lung-RADS 4 was 28.6% (95% CI 21.6-36.8).

CONCLUSION: Lung-RADS scores and PPV rates in the literature are not aligned with the ACR's own estimates, suggesting that perhaps Lung-RADS categorization needs to be reexamined for better concordance with real-world screening populations. In addition to serving as a benchmark before screening guideline broadening, this study provides guidance for future reporting of lung cancer screening and Lung-RADS data.

来源:J Am Coll Radiol,查看原文。版权归原作者所有。

引用

  1. Gu JZ, Baird GL, Ge C, et al. ACR Lung CT Screening Reporting and Data System, a Systematic Review and Meta-Analysis Before Change in US Preventative Services Taskforce Eligibility Criteria: 2014 to 2021. J Am Coll Radiol. 2023. PMID: 37301355. doi:10.1016/j.jacr.2023.04.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。